We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Boston Scientific Corporation | NYSE:BSX | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 72.72 | 7 | 10:14:35 |
From May 2023 to May 2024
By Colin Kellaher
Boston Scientific has agreed to acquire smaller medical-technology company Relievant Medsystems for an initial $850 million in cash in a deal that expands its portfolio of treatments for chronic low back pain.
Boston Scientific on Tuesday said Relievant's Intracept intraosseous nerve ablation system is approved by the U.S. Food and Drug Administration to treat vertebrogenic pain, a form of chronic low back pain.
Boston Scientific said Relievant expects to generate sales of more than $70 million this year, with sales growth topping 50% in 2024.
The Marlborough, Mass., company said it expects to complete the acquisition in the first half of 2024, adding that the deal carries undisclosed additional contingent payments based on Relievant's sales performance over the next three years.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
September 19, 2023 07:30 ET (11:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Boston Scientific Chart |
1 Month Boston Scientific Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
